The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α

Studying the role of circulatory factors in the pathogenesis of diseases has been key to the development of effective therapies. We sought to examine the effect of antihypertensive therapies on numerous circulatory factors including short chain fatty acids and growth factors in a human cohort. A subset of participants from an earlier study was characterized by their hypertensive and/or treatment status and separated into three groups: (i) normotensives; (ii) untreated hypertensive and (iii) treated hypertensive subjects. Circulating levels of short chain fatty acids, FGF21 and TNF superfamily members were measured as part of this study. Both F2-isoprostane and circulating lipid levels were reanalysed as part of this current study. We found that antihypertensive treatment increased butyrate levels and decreased acetate levels to levels similar to normotensives. We also found that antihypertensive treatments reduced levels of circulating FGF21, TNFSF14 and TNF-α. In conclusion, we identified several circulatory factors that are altered in hypertension.

[1]  R. Rosenson,et al.  HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk. , 2021, European journal of preventive cardiology.

[2]  J. Duarte,et al.  Microbiota and hypertension: role of the sympathetic nervous system and the immune system. , 2020, American journal of hypertension.

[3]  E. Rakoczy,et al.  Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice , 2020, World journal of gastroenterology.

[4]  G. Qiao,et al.  FGF-21 ameliorates essential hypertension of SHR via baroreflex afferent function , 2020, Brain Research Bulletin.

[5]  A. Magno,et al.  SGLT2 Inhibitor–Induced Sympathoinhibition , 2020, JACC. Basic to translational science.

[6]  Kai Yin,et al.  High-density lipoprotein-mediated cardioprotection in heart failure , 2020, Heart Failure Reviews.

[7]  C. L. Lim,et al.  Age‐related bone loss is associated with FGF21 but not IGFBP1 in healthy adults , 2020, Experimental physiology.

[8]  Hui-tao Zhang,et al.  Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice , 2019, Drug design, development and therapy.

[9]  A. Magno,et al.  The Schlager mouse as a model of altered retinal phenotype , 2019, Neural regeneration research.

[10]  Jai-Sing Yang,et al.  High-density lipoprotein ameliorates palmitic acid-induced lipotoxicity and oxidative dysfunction in H9c2 cardiomyoblast cells via ROS suppression , 2019, Nutrition & Metabolism.

[11]  D. Kaye,et al.  The gut microbiota and blood pressure in experimental models , 2019, Current opinion in nephrology and hypertension.

[12]  F. O'Gara,et al.  Isoquercetin and inulin synergistically modulate the gut microbiome to prevent development of the metabolic syndrome in mice fed a high fat diet , 2018, Scientific Reports.

[13]  Y. Wang,et al.  FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice. , 2018, Cell metabolism.

[14]  N. Ward,et al.  Shining LIGHT on the metabolic role of the cytokine TNFSF14 and the implications on hepatic IL‐6 production , 2018, Immunology and cell biology.

[15]  H. Häring,et al.  Fibroblast Growth Factor 21—Metabolic Role in Mice and Men , 2017, Endocrine reviews.

[16]  V. Matthews,et al.  Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2 , 2017, Journal of hypertension.

[17]  Shenghui Li,et al.  Alterations of the Gut Microbiome in Hypertension , 2017, Front. Cell. Infect. Microbiol..

[18]  F. O'Gara,et al.  Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism , 2017, Microbiome.

[19]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[20]  Xiaolong Lin,et al.  Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues , 2017, Biomedical reports.

[21]  Y. Okada,et al.  The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice , 2017, International journal of molecular sciences.

[22]  B. Cheung,et al.  The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension , 2017, Current Hypertension Reports.

[23]  A. El-Osta,et al.  High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice , 2017, Circulation.

[24]  W. Shou,et al.  FGF21 ameliorates the neurocontrol of blood pressure in the high fructose-drinking rats , 2016, Scientific Reports.

[25]  S. Blackwell,et al.  Transglutaminase is a Critical Link Between Inflammation and Hypertension , 2016, Journal of the American Heart Association.

[26]  Mark D. Huffman,et al.  The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke A Modeling Study From the American Heart Association and World Heart Federation , 2016, Circulation.

[27]  E. Maratos-Flier,et al.  Understanding the Physiology of FGF21. , 2016, Annual review of physiology.

[28]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[29]  Jiang He,et al.  Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. , 2015, Circulation.

[30]  Xiaomin Sun,et al.  Cardiorespiratory fitness and visceral fat are key determinants of serum fibroblast growth factor 21 concentration in Japanese men. , 2014, The Journal of clinical endocrinology and metabolism.

[31]  S. Takai,et al.  Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients , 2014, Journal of Human Hypertension.

[32]  Lieping Chen,et al.  Excess LIGHT Contributes to Placental Impairment, Increased Secretion of Vasoactive Factors, Hypertension, and Proteinuria in Preeclampsia , 2014, Hypertension.

[33]  G. Koliakos,et al.  Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection , 2013, Journal of pharmacy & bioallied sciences.

[34]  L. Ferrucci,et al.  Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults , 2013, Journal of Human Hypertension.

[35]  J. Blangero,et al.  ADAM28 is elevated in humans with the metabolic syndrome and is a novel sheddase of human tumour necrosis factor‐α , 2012, Immunology and cell biology.

[36]  H. J. Yoo,et al.  Effects of a three‐month combined exercise programme on fibroblast growth factor 21 and fetuin‐A levels and arterial stiffness in obese women , 2011, Clinical endocrinology.

[37]  E. Arnesen,et al.  Associations of age with serum insulin, proinsulin and the proinsulin-to-insulin ratio: a cross-sectional study , 2010, BMC endocrine disorders.

[38]  M. Martínez-Chantar,et al.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[39]  Z. Jia,et al.  Age‐related alterations of gene expression patterns in human CD8+ T cells , 2010, Aging cell.

[40]  M. Matoulek,et al.  Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor‐21 in patients with type 2 diabetes and obesity , 2009, Clinical endocrinology.

[41]  K. Safranow,et al.  Platelets arachidonic acid metabolism in patients with essential hypertension , 2009, Platelets.

[42]  R. Natarajan,et al.  Proinflammatory Effects of Advanced Lipoxidation End Products in Monocytes , 2008, Diabetes.

[43]  R. Rodrigo,et al.  Relationship between Oxidative Stress and Essential Hypertension , 2007, Hypertension Research.

[44]  A. Swislocki,et al.  Effects of antihypertensives on glucose metabolism. , 2007, Metabolic syndrome and related disorders.

[45]  A. Mainous,et al.  Prehypertension and Cardiovascular Morbidity , 2005, The Annals of Family Medicine.

[46]  S. Hsu,et al.  Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF alpha-caspase signaling pathway. , 2004, Cardiovascular research.

[47]  J. Hodgson,et al.  Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. , 2004, Free radical biology & medicine.

[48]  M. Orellana,et al.  Implications of Oxidative Stress and Homocysteine in the Pathophysiology of Essential Hypertension , 2003, Journal of cardiovascular pharmacology.

[49]  G. Lip,et al.  ABC of hypertension: The pathophysiology of hypertension. , 2001, BMJ.

[50]  N. Aki,et al.  Correlation of fibroblast growth factor 21 serum levels with metabolic parameters in Japanese subjects. , 2000, The journal of medical investigation : JMI.

[51]  G. Burmester,et al.  Preactivated peripheral blood monocytes in patients with essential hypertension. , 1999, Hypertension.

[52]  T. Mori,et al.  An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. , 1999, Analytical biochemistry.

[53]  G. Paolisso,et al.  Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. , 1998, The American journal of physiology.

[54]  B. Zinman,et al.  Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. , 1999, The Journal of clinical endocrinology and metabolism.